Journal of Clinical Toxicology
Open Access

B. E. Ruck2

Publications

• Case Report
  Iatrogenic Opioid-withdrawal Induced by Contrave®
  Author(s): M. J. Zylstra, B. E. Ruck2 and S. M. Marcus M. J. Zylstra, B. E. Ruck2 and S. M. Marcus
  
  Introduction: New medications for the management of obesity are rapidly coming through the drug design pipeline. Among those recently approved is Contrave®, [naltrexone/bupropion] which has shown a modest and clinically relevant weight loss. We report two cases of naltrexone-induced opioid withdrawal resulting from the prescription of Contrave® to opioid-dependent patients. Case details: Patient 1 was a 59-year-old male with chronic pain prescribed morphine 60 mg and oxycodone 30 mg daily. He was prescribed Contrave® as adjunct to lifestyle modifications in the management of his obesity. Withdrawal symptoms precipitated within a few hours of his first dose. The resultant vomiting and anxiety led to patient distress and an emergency department visit. Patient 2 was a 42-year-old female former heroin user on methadone maintenance 90 mg daily. She was started on Contrave® .. View More»
  DOI: 10.4172/2161-0495.1000289

  Abstract PDF

Relevant Topics